David R Holmes

Author PubWeight™ 480.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009 17.17
2 Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003 13.29
3 Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014 10.54
4 Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002 4.99
5 Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004 4.62
6 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014 4.57
7 Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013 4.34
8 Drug-eluting coronary-artery stents. N Engl J Med 2013 3.69
9 Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol 2011 3.66
10 Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010 3.47
11 Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 2013 3.41
12 Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011 3.29
13 Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience. Catheter Cardiovasc Interv 2005 3.20
14 Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011 3.16
15 Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007 2.88
16 Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 2013 2.88
17 Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003 2.81
18 Transcatheter aortic valve implantation: assessing the learning curve. JACC Cardiovasc Interv 2011 2.63
19 Myocardial bridging. Eur Heart J 2005 2.56
20 Trends in cause of death after percutaneous coronary intervention. Circulation 2014 2.52
21 Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003 2.52
22 Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol 2005 2.51
23 Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv 2010 2.51
24 Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol 2007 2.47
25 Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 2007 2.47
26 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012 2.44
27 Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008 2.42
28 Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004 2.42
29 Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2010 2.40
30 Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004 2.32
31 Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007 2.31
32 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 2.30
33 Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006 2.29
34 Chronic total occlusion angioplasty in the United States. JACC Cardiovasc Interv 2009 2.24
35 Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: a long-term follow-up study. J Am Coll Cardiol 2005 2.21
36 Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). Circulation 2003 2.21
37 Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc 2004 2.11
38 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 2.04
39 Volume-outcome relationships for percutaneous coronary interventions in the stent era. Circulation 2005 2.03
40 The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002 2.03
41 Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010 2.00
42 Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation 2002 2.00
43 Rheolytic thrombectomy with Angiojet in thrombus-containing lesions. Catheter Cardiovasc Interv 2002 1.98
44 The history of the German Cardiac Society and the American College of Cardiology and their two founders. J Am Coll Cardiol 2013 1.97
45 ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010 1.92
46 Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007 1.91
47 Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 2006 1.90
48 Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002 1.88
49 Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004 1.87
50 Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Circulation 2012 1.87
51 Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009 1.87
52 ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010 1.86
53 A risk score to predict in-hospital mortality for percutaneous coronary interventions. J Am Coll Cardiol 2006 1.84
54 Clinical determinants of radiation dose in percutaneous coronary interventional procedures: influence of patient size, procedure complexity, and performing physician. JACC Cardiovasc Interv 2011 1.80
55 Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol 2008 1.78
56 Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2012 1.77
57 Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents. Circulation 2008 1.77
58 Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac Surg 2011 1.77
59 Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J 2013 1.76
60 Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc 2002 1.74
61 Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv 2010 1.74
62 Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registry. J Am Coll Cardiol 2003 1.74
63 Coronary stent restenosis in patients treated with cilostazol. Circulation 2005 1.73
64 Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med 2011 1.70
65 Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol 2007 1.68
66 Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008 1.67
67 Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv 2011 1.66
68 The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J 2006 1.65
69 Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. Eur Heart J 2006 1.63
70 Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 2002 1.62
71 Myocardial bridging in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003 1.62
72 Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J 2004 1.60
73 Long-term mortality of coronary artery bypass grafting and bare-metal stenting. Ann Thorac Surg 2011 1.60
74 30-day readmission for patients undergoing percutaneous coronary interventions in New York state. JACC Cardiovasc Interv 2011 1.59
75 Enhanced external counterpulsation for ischemic heart disease: what's behind the curtain? J Am Coll Cardiol 2003 1.59
76 Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002 1.57
77 Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv 2011 1.56
78 The truth and consequences of the COURAGE trial. J Am Coll Cardiol 2007 1.55
79 Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation 2004 1.54
80 Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 2005 1.54
81 Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J 2008 1.53
82 Medical device innovation: prospective solutions for an ecosystem in crisis. Adding a professional society perspective. JACC Cardiovasc Interv 2012 1.53
83 Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation 2012 1.52
84 Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis. JAMA 2011 1.51
85 Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial. Catheter Cardiovasc Interv 2012 1.51
86 Staged versus one-time complete revascularization with percutaneous coronary intervention for multivessel coronary artery disease patients without ST-elevation myocardial infarction. Circ Cardiovasc Interv 2013 1.51
87 Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004 1.51
88 Turf wars and silos-joined at the hip: what can be done? Catheter Cardiovasc Interv 2007 1.50
89 Low-risk percutaneous coronary interventions without on-site cardiac surgery: two years' observational experience and follow-up. Am Heart J 2003 1.50
90 Location of femoral artery access and correlation with vascular complications. Catheter Cardiovasc Interv 2011 1.50
91 Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004 1.50
92 Transcatheter valve therapy: a professional society overview from the American College of Cardiology Foundation and the Society of Thoracic Surgeons. Ann Thorac Surg 2011 1.49
93 Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008 1.49
94 Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. JAMA 2011 1.48
95 Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 2004 1.48
96 Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. Ann Thorac Surg 2016 1.48
97 Immediate ambulation following diagnostic coronary angiography procedures utilizing a vascular closure device (The Closer). J Invasive Cardiol 2002 1.47
98 Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J 2004 1.47
99 Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv 2010 1.47
100 Statistical SPECT processing in MRI-negative epilepsy surgery. Neurology 2014 1.46
101 Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv 2008 1.45
102 The New York State risk score for predicting in-hospital/30-day mortality following percutaneous coronary intervention. JACC Cardiovasc Interv 2013 1.45
103 Incidence, correlates, management, and clinical outcome of coronary perforation: analysis of 16,298 procedures. Am Heart J 2004 1.43
104 Analysis of stroke occurring in the SYNTAX trial comparing coronary artery bypass surgery and percutaneous coronary intervention in the treatment of complex coronary artery disease. JACC Cardiovasc Interv 2013 1.42
105 Economic and clinical outcomes of a physician-led continuous quality improvement intervention in the delivery of percutaneous coronary intervention. Am J Manag Care 2006 1.42
106 ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization : a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology. Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Catheter Cardiovasc Interv 2009 1.41
107 Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003 1.41
108 Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007 1.40
109 Neuroimaging patterns of ischemic stroke after percutaneous coronary intervention. Catheter Cardiovasc Interv 2014 1.40
110 Sustaining improvement in door-to-balloon time over 4 years: the Mayo clinic ST-elevation myocardial infarction protocol. Circ Cardiovasc Qual Outcomes 2009 1.40
111 Outcomes for patients with ST-elevation myocardial infarction in hospitals with and without onsite coronary artery bypass graft surgery: the New York State experience. Circ Cardiovasc Interv 2009 1.40
112 Percutaneous coronary intervention for ST-segment and non-ST-segment elevation myocardial infarction at hospitals with and without on-site cardiac surgical capability. Mayo Clin Proc 2004 1.40
113 Constrictive pericarditis in the modern era: novel criteria for diagnosis in the cardiac catheterization laboratory. J Am Coll Cardiol 2008 1.39
114 Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents. Catheter Cardiovasc Interv 2008 1.39
115 Sirolimus-eluting coronary stents in octogenarians: a 1-year analysis of the worldwide e-SELECT Registry. JACC Cardiovasc Interv 2011 1.39
116 Safety and efficacy of cutting balloon angioplasty: the Mayo Clinic experience. J Invasive Cardiol 2002 1.39
117 Clinical presentation, investigation, and management of pulmonary vein stenosis complicating ablation for atrial fibrillation. Circulation 2005 1.38
118 Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention. Mayo Clin Proc 2008 1.38
119 Magnetic navigation facilitates percutaneous coronary intervention for complex lesions. Catheter Cardiovasc Interv 2013 1.38
120 Neointimal progression and luminal narrowing in sirolimus-eluting stent treatment for bare metal in-stent restenosis: a quantitative intravascular ultrasound analysis. Am Heart J 2007 1.38
121 Percutaneous coronary intervention in native vessels with angiographically visible thrombus temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv 2010 1.38
122 Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. Circulation 2009 1.37
123 Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J 2010 1.36
124 Percutaneous closure of congenital coronary artery fistulae: results and angiographic follow-up. JACC Cardiovasc Interv 2011 1.32
125 Transcatheter valve therapy a professional society overview from the american college of cardiology foundation and the society of thoracic surgeons. J Am Coll Cardiol 2011 1.30
126 Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol 2002 1.29
127 Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). Am J Cardiol 2010 1.27
128 Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009 1.26
129 Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012 1.20
130 Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 2004 1.20
131 Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. Mayo Clin Proc 2007 1.19
132 Impact of age on procedural and 1-year outcome in percutaneous transluminal coronary angioplasty: a report from the NHLBI Dynamic Registry. Am Heart J 2003 1.19
133 Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 2006 1.18
134 Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both? Eur Heart J 2007 1.17
135 Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol 2002 1.15
136 Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. JACC Cardiovasc Interv 2009 1.13
137 Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J 2011 1.13
138 The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J 2006 1.10
139 Twenty-five-year trends in in-hospital and long-term outcome after percutaneous coronary intervention: a single-institution experience. Circulation 2007 1.10
140 Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 2008 1.10
141 Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005 1.10
142 Intravascular ultrasound for intracranial angioplasty and stent placement: technical case report. Neurosurgery 2006 1.10
143 Prediction of complications following nonemergency percutaneous coronary interventions. Am J Cardiol 2005 1.09
144 ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Thorac Cardiovasc Surg 2012 1.09
145 Appropriateness of coronary revascularization for patients without acute coronary syndromes. J Am Coll Cardiol 2012 1.08
146 Long-term outcome of patients treated with repeat percutaneous coronary intervention after failure of gamma-brachytherapy for the treatment of in-stent restenosis. Circulation 2002 1.08
147 Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 2008 1.07
148 Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv 2008 1.07
149 Complex coronary anatomy in coronary artery bypass graft surgery: impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years. J Thorac Cardiovasc Surg 2011 1.07
150 Left main coronary artery stenosis: state-of-the-art. Curr Probl Cardiol 2007 1.07
151 Predictors and outcomes of ad hoc versus non-ad hoc percutaneous coronary interventions. JACC Cardiovasc Interv 2009 1.07
152 Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort. Catheter Cardiovasc Interv 2008 1.07
153 Response to letter regarding article, "Quantification of incomplete revascularization and its association with five-year mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: validation of the residual SYNTAX Score". Circulation 2014 1.05
154 Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005 1.04
155 Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary intervention and is a valid quality indicator. J Am Coll Cardiol 2005 1.04
156 ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. Circulation 2011 1.04
157 The STS-ACC transcatheter valve therapy national registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies. J Am Coll Cardiol 2013 1.04
158 Effect of lesion length on fractional flow reserve in intermediate coronary lesions. Am Heart J 2005 1.03
159 Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. J Am Coll Cardiol 2006 1.02
160 A total of 1,007 percutaneous coronary interventions without onsite cardiac surgery: acute and long-term outcomes. J Am Coll Cardiol 2006 1.01
161 Adjunctive thrombectomy and distal protection in primary percutaneous coronary intervention: impact on microvascular perfusion and outcomes. Circulation 2009 1.01
162 Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 2004 1.00
163 Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc 2009 1.00
164 Comparison of Mayo Clinic risk score and American College of Cardiology/American Heart Association lesion classification in the prediction of adverse cardiovascular outcome following percutaneous coronary interventions. J Am Coll Cardiol 2004 1.00
165 Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). J Am Coll Cardiol 2012 0.99
166 Intravascular ultrasound identification of intraluminal embolic plaque material during carotid angioplasty with stenting. Catheter Cardiovasc Interv 2006 0.99
167 Early direct coronary angioplasty in survivors of out-of-hospital cardiac arrest. Am J Cardiol 2003 0.99
168 Circadian variation in coronary stent thrombosis. JACC Cardiovasc Interv 2011 0.99
169 Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol 2003 0.99
170 "Familial" apical ballooning syndrome (Takotsubo cardiomyopathy). Int J Cardiol 2009 0.99
171 Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002 0.98
172 Rational dispersion for the introduction of transcatheter valve therapy. JAMA 2011 0.98
173 Temporal trends (over 30 years), clinical characteristics, outcomes, and gender in patients ≤50 years of age having percutaneous coronary intervention. Am J Cardiol 2011 0.98
174 Trends in the association between age and in-hospital mortality after percutaneous coronary intervention: National Cardiovascular Data Registry experience. Circ Cardiovasc Interv 2009 0.97
175 Macrophages, myofibroblasts and neointimal hyperplasia after coronary artery injury and repair. Atherosclerosis 2002 0.97
176 Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 2002 0.97
177 Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J 2003 0.96
178 How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease? Eur Heart J 2010 0.96
179 Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation 2004 0.96
180 Safety of same-day coronary angiography in patients undergoing elective valvular heart surgery. Mayo Clin Proc 2007 0.96
181 Successful radiofrequency ablation of the cerebral cortex in pigs using the venous system: possible implications for treating CNS disorders. Epilepsy Res 2008 0.95
182 Differences in utilization of drug-eluting stents by race and payer. Am J Cardiol 2007 0.95
183 The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. Eur Heart J 2013 0.94
184 Chronic antioxidant supplementation attenuates nuclear factor-kappa B activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res 2002 0.94
185 Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol 2002 0.94
186 Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation 2006 0.94
187 Coronary artery fistula: single-center experience spanning 17 years. J Interv Cardiol 2007 0.93
188 Recent trends in the percutaneous treatment of chronic total coronary occlusions. Am J Cardiol 2006 0.93
189 Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycemic agents. Am J Cardiol 2004 0.93
190 Three-dimensional volumetric computed tomographic scoring as an objective outcome measure for chronic rhinosinusitis: clinical correlations and comparison to Lund-Mackay scoring. Int Forum Allergy Rhinol 2013 0.93
191 Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004 0.92
192 Routine intravascular ultrasound guidance of percutaneous coronary intervention: a critical reappraisal. J Am Coll Cardiol 2004 0.92
193 Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Am Coll Cardiol 2002 0.92
194 Plaque characteristics and arterial remodeling in coronary and peripheral arterial systems. Atherosclerosis 2012 0.92
195 Appropriateness of diagnostic catheterization for suspected coronary artery disease in New York State. Circ Cardiovasc Interv 2014 0.92
196 Drug-eluting stents: a study of international practice. Am Heart J 2009 0.92
197 Risk stratification for long-term mortality after percutaneous coronary intervention. Circ Cardiovasc Interv 2014 0.92
198 Effect of onset-to-door time and door-to-balloon time on mortality in patients undergoing percutaneous coronary interventions for st-segment elevation myocardial infarction. Am J Cardiol 2010 0.91
199 Management of pulmonary vein rupture after percutaneous intervention: utility of a hybrid approach. Ann Thorac Surg 2013 0.91
200 Completeness of revascularization for multivessel coronary artery disease and its effect on one-year outcome: a report from the NHLBI Dynamic Registry. J Interv Cardiol 2007 0.91
201 Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol 2006 0.91
202 Accuracy considerations in image-guided cardiac interventions: experience and lessons learned. Int J Comput Assist Radiol Surg 2011 0.90
203 The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. J Am Coll Cardiol 2012 0.90
204 Impact of incomplete revascularization on long-term mortality after coronary stenting. Circ Cardiovasc Interv 2011 0.90
205 Clinical risk stratification in the emergency department predicts long-term cardiovascular outcomes in a population-based cohort presenting with acute chest pain: primary results of the Olmsted county chest pain study. Medicine (Baltimore) 2009 0.90
206 Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2002 0.90
207 From randomized trials to registry studies: translating data into clinical information. Nat Clin Pract Cardiovasc Med 2008 0.90
208 Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005 0.89
209 Independent association between symptom onset time and infarct size in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Chronobiol Int 2014 0.89
210 Radiation dose reduction in the invasive cardiovascular laboratory: implementing a culture and philosophy of radiation safety. JACC Cardiovasc Interv 2012 0.89
211 Infectious complications of percutaneous vascular closure devices. Mayo Clin Proc 2005 0.88
212 Alveolar hemorrhage associated with periprocedural eptifibatide administration. J Invasive Cardiol 2004 0.88
213 Drug-eluting stents in octogenarians: early and intermediate outcome. Am Heart J 2008 0.88
214 ACCF 2008 Training Statement on Multimodality Noninvasive Cardiovascular Imaging A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training Developed in Collaboration With the American Society of Echocardiography, the American Society of Nuclear Cardiology, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society for Vascular Medicine. J Am Coll Cardiol 2009 0.88
215 Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes. J Am Coll Cardiol 2002 0.88
216 ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance. A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol 2007 0.88
217 Carotid artery stenting versus surgery: adequate comparisons? Lancet Neurol 2010 0.87
218 Temporal trends and improved outcomes of percutaneous coronary revascularization in nonagenarians. JACC Cardiovasc Interv 2008 0.87
219 Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. Eur Heart J 2012 0.86
220 Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. J Am Coll Cardiol 2004 0.86
221 Procedural factors associated with percutaneous coronary intervention-related ischemic stroke. JACC Cardiovasc Interv 2012 0.86
222 Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease. Circ Cardiovasc Interv 2012 0.86
223 A critical appraisal of current models of risk stratification for percutaneous coronary interventions. Am Heart J 2005 0.86
224 An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIb trial. Am J Med 2003 0.86
225 Strain rate imaging for assessment of regional myocardial function: results from a clinical model of septal ablation. Circulation 2002 0.86
226 Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J 2010 0.86
227 Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Eur Heart J 2012 0.86
228 Chronic kidney disease as a cardiovascular risk factor. Am Heart J 2003 0.85
229 A prospective, case-control study of tobacco dependence in thromboangiitis obliterans (Buerger's Disease). Angiology 2006 0.85
230 Task force 3: training in diagnostic and interventional cardiac catheterization endorsed by the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2008 0.85
231 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Catheter Cardiovasc Interv 2012 0.85
232 Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J 2007 0.85
233 Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2009 0.85
234 Outcome of patients with prior percutaneous revascularization undergoing repeat coronary intervention (from the PRESTO Trial). Am J Cardiol 2005 0.85
235 Balloon aortic valvuloplasty under temporary mechanical circulatory support as a bridge to aortic valve replacement in a patient with hemodynamic failure secondary to critical aortic valve stenosis. Heart Surg Forum 2012 0.85
236 Left atrial appendage closure. Curr Cardiol Rep 2010 0.85
237 Trends, predictors, and outcomes of cerebrovascular events related to percutaneous coronary intervention: a 16-year single-center experience. JACC Cardiovasc Interv 2011 0.85
238 Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment. Am Heart J 2003 0.84
239 Centerline tracking for quantification of reverse structural remodeling of the pulmonary veins following cardiac ablation therapy. Acad Radiol 2012 0.84
240 Routine intravascular ultrasound scanning guidance of coronary stenting is not associated with improved clinical outcomes. Am Heart J 2004 0.84
241 In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction. Am J Cardiol 2005 0.84
242 Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal. J Am Coll Cardiol 2002 0.84
243 A pathobiologic link between risk factors profile and morphological markers of carotid instability. Atherosclerosis 2009 0.84
244 Drug-eluting coronary stents. Curr Probl Cardiol 2006 0.84
245 Left atrial appendage occlusion for stroke prevention. Curr Probl Cardiol 2012 0.83
246 Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). Am J Cardiol 2008 0.83
247 Outcomes in diabetics undergoing revascularization: the long and the short of it. J Am Coll Cardiol 2002 0.83
248 C-reactive protein relaxes human vessels in vitro. Arterioscler Thromb Vasc Biol 2002 0.83
249 Is the left atrial appendage more than a simple appendage? Catheter Cardiovasc Interv 2009 0.82
250 A tissue-engineered stent for cell-based vascular gene transfer. Hum Gene Ther 2002 0.82
251 On mixed reality environments for minimally invasive therapy guidance: systems architecture, successes and challenges in their implementation from laboratory to clinic. Comput Med Imaging Graph 2013 0.82
252 Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 2002 0.82
253 Prevention and management of contrast-induced acute kidney injury. Curr Treat Options Cardiovasc Med 2012 0.82
254 3-Dimensional bifurcation angle analysis in patients with left main disease: a substudy of the SYNTAX trial (SYNergy Between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery). JACC Cardiovasc Interv 2010 0.82
255 Location of coronary culprit lesions at autopsy in 41 nondiabetic patients with acute myocardial infarction. Am J Forensic Med Pathol 2010 0.82
256 Incomplete revascularization is associated with greater risk of long-term mortality after stenting in the era of first generation drug-eluting stents. Am J Cardiol 2013 0.82
257 Pilot multi-reader study demonstrating potential for dose reduction in dual energy hepatic CT using non-linear blending of mixed kV image datasets. Eur Radiol 2010 0.82
258 Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions <or=40%, 41% to 49%, and >or=50% having percutaneous coronary revascularization. Am J Cardiol 2003 0.82
259 Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial). Am J Cardiol 2006 0.81
260 Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. JACC Cardiovasc Interv 2012 0.81
261 Proteinuria, serum creatinine, and outcome of percutaneous coronary intervention in patients with diabetes mellitus. Am J Cardiol 2002 0.81
262 A comparison of mortality, myocardial infarction, and repeated revascularization for sirolimus-eluting and paclitaxel-eluting coronary stents. Am Heart J 2007 0.81
263 The clinical development of percutaneous heart valve technology: a position statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society for Cardiovascular Angiography and Interventions (SCAI). Ann Thorac Surg 2005 0.81
264 Electromagnetic interference of magnetic field based auto identification technologies in healthcare settings. Int J Med Inform 2011 0.81
265 Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials. Eur Heart J 2003 0.81
266 Relation of preprocedural statin therapy to in-hospital procedural complications following percutaneous coronary interventions in patients with hyperlipidemia. Am J Cardiol 2006 0.81
267 Endothelin type A receptor antagonism restores myocardial perfusion response to adenosine in experimental hypercholesterolemia. Atherosclerosis 2003 0.81
268 Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. JACC Cardiovasc Interv 2010 0.81
269 Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2008 0.81
270 The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy. EuroIntervention 2013 0.81
271 Intracardiac echocardiography in the interventional catheterization laboratory: preliminary experience with a novel, phased-array transducer. Am J Cardiol 2002 0.80
272 Drug-eluting coronary-artery stents. N Engl J Med 2013 0.80
273 Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction. Am Heart J 2003 0.80
274 Underutilization of percutaneous coronary intervention for ST-elevation myocardial infarction in medicaid patients relative to private insurance patients. J Interv Cardiol 2013 0.80
275 Left atrial appendage obliteration: mechanisms of healing and intracardiac integration. JACC Cardiovasc Interv 2010 0.80
276 Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. JACC Cardiovasc Interv 2010 0.80
277 Development and validation of risk adjustment models for long-term mortality and myocardial infarction following percutaneous coronary interventions. Circ Cardiovasc Interv 2010 0.80
278 Relation of Thrombolysis in Myocardial Infarction (TIMI) frame count to coronary flow parameters. Am J Cardiol 2003 0.80
279 The clinical development of percutaneous heart valve technology: a position statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society for Cardiovascular Angiography and Interventions (SCAI) Endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA). J Am Coll Cardiol 2005 0.80
280 A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. JACC Cardiovasc Interv 2012 0.80
281 The association of serum uric acid levels with outcomes following percutaneous coronary intervention. J Interv Cardiol 2010 0.80
282 A technical and cognitive skills evaluation of performance in interventional cardiology procedures using medical simulation. Simul Healthc 2010 0.80
283 And the answer is, it doesn't much matter. Circulation 2002 0.80
284 Comparison of drug-eluting and bare-metal stents for stable coronary artery disease. JACC Cardiovasc Interv 2009 0.80
285 Drug-drug interactions in cardiovascular catheterizations and interventions. JACC Cardiovasc Interv 2012 0.79
286 Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. J Am Coll Cardiol 2006 0.79
287 Thirty-year trends in outcomes of percutaneous coronary interventions in diabetic patients. Mayo Clin Proc 2013 0.79
288 Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction. Mayo Clin Proc 2007 0.79
289 Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). Am J Cardiol 2007 0.79
290 TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium. Am Heart J 2013 0.79
291 Effect of septal ablation on myocardial relaxation and left atrial pressure in hypertrophic cardiomyopathy an invasive hemodynamic study. JACC Cardiovasc Interv 2008 0.79
292 Applicability of distal protection for aortocoronary vein graft interventions in clinical practice. Catheter Cardiovasc Interv 2004 0.79
293 The clinical development of percutaneous heart valve technology: a position statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society of Cardiovascular Angiography and Intervention (SCAI). Catheter Cardiovasc Interv 2005 0.79
294 The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy. EuroIntervention 2013 0.79
295 Sudden cardiac death: epidemiology, circadian variation, and triggers. Curr Probl Cardiol 2011 0.79
296 American College of Cardiology/American Heart Association 2006 update of the clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion: a report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training: developed in collaboration with the Heart Rhythm Society. Circulation 2006 0.78
297 Comparison of outcomes for patients receiving drug-eluting versus bare metal stents for non-ST-segment elevation myocardial infarction. Am J Cardiol 2011 0.78
298 ACCF/AHA/SCAI 2007 update of the clinical competence statement on cardiac interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures). J Am Coll Cardiol 2007 0.78
299 Feasibility of dose reduction using novel denoising techniques for low kV (80 kV) CT enterography: optimization and validation. Acad Radiol 2010 0.78
300 Interventional fellowship in structural and congenital heart disease for adults. JACC Cardiovasc Interv 2010 0.78
301 Comparison of patients undergoing enhanced external counterpulsation and percutaneous coronary intervention for stable angina pectoris. Am J Cardiol 2002 0.78
302 Patent foramen ovale, systemic embolization, and closure. Curr Probl Cardiol 2009 0.78
303 The fate of patients with clinical recurrence after sirolimus-eluting stent implantation (a two-year follow-up analysis from the SIRIUS trial). Am J Cardiol 2006 0.78
304 Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation. Am Heart J 2006 0.78
305 Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency. Mayo Clin Proc 2010 0.78
306 ACCF/AHA/SCAI 2007 update of the Clinical Competence Statement on Cardiac Interventional Procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures). Circulation 2007 0.78
307 Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State. Catheter Cardiovasc Interv 2013 0.78
308 Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007 0.78
309 American College of Cardiology/American Heart Association 2006 update of the clinical competence statement on invasive electrophysiologystudies,catheterablation,andcardioversion: a report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training developed in collaboration with the Heart Rhythm Society. J Am Coll Cardiol 2006 0.78
310 Association of race with complications and prognosis following acute coronary syndromes. Am J Cardiol 2004 0.77
311 Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2005 0.77
312 Importance of the postdischarge interval in assessing major adverse clinical event rates following percutaneous coronary intervention. Am J Cardiol 2005 0.77
313 Outcomes after coronary stent implantation in patients with metal allergy. Circ Cardiovasc Interv 2012 0.77
314 Temporal variation in inhospital mortality with percutaneous coronary intervention: a report from the National Heart, Lung and Blood Institute Dynamic Registry. Am Heart J 2005 0.77
315 Variability in fluoroscopic X-ray exposure in contemporary cardiac catheterization laboratories. J Am Coll Cardiol 2006 0.77
316 Impact of prehospital electrocardiogram protocol and immediate catheterization team activation for patients with ST-elevation-myocardial infarction. Circ Cardiovasc Qual Outcomes 2011 0.77
317 Outcome and quality of care of patients who have acute myocardial infarction. Med Clin North Am 2007 0.77
318 Surgical and percutaneous management of carotid artery stenosis. Curr Probl Cardiol 2008 0.77
319 Images in Cardiology Imaging the coronary microcirculation: 3D micro-CT of coronary vasa vasorum. Int J Cardiovasc Intervent 1999 0.77
320 Stroke prevention in atrial fibrillation: WATCHMAN versus warfarin. Expert Rev Cardiovasc Ther 2009 0.77
321 Improving cardiovascular health: a balance between discovery and delivery. JAMA 2013 0.77
322 Beyond the learning curve: transapical versus transfemoral transcatheter aortic valve replacement in the treatment of severe aortic valve stenosis. J Card Surg 2014 0.77
323 Sex-related differences in fractional flow reserve-guided treatment. Circ Cardiovasc Interv 2013 0.77
324 Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis. BMC Med Genomics 2011 0.77
325 Non-surgical left atrial appendage closure for stroke prevention in atrial fibrillation. J Cardiovasc Electrophysiol 2011 0.77
326 Observer performance for adaptive, image-based denoising and filtered back projection compared to scanner-based iterative reconstruction for lower dose CT enterography. Abdom Imaging 2015 0.77
327 The COURAGE trial in perspective. Catheter Cardiovasc Interv 2008 0.77
328 Time-trend analysis on the Framingham risk score and prevalence of cardiovascular risk factors in patients undergoing percutaneous coronary intervention without prior history of coronary vascular disease over the last 17 years: a study from the Mayo Clinic PCI registry. Clin Cardiol 2014 0.77
329 A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions. Value Health 2008 0.76
330 Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation. Circulation 2002 0.76
331 Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial. Am Heart J 2012 0.76
332 Was your mother right--do we always need to close the door? Circulation 2002 0.76
333 Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv 2012 0.76
334 Usefulness of diabetes mellitus to predict long-term outcomes in patients with unstable angina pectoris. Am J Cardiol 2009 0.76
335 How do we get there from here-is it safe and in whose hands? J Cardiovasc Electrophysiol 2005 0.76
336 Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". Am Heart J 2011 0.76
337 ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training: developed in collaboration with the Society of Atherosclerosis Imaging and Prevention, the Society for Cardiovascular Angiography and Interventions, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society for Vascular Medicine and Biology. Circulation 2007 0.76
338 Percutaneous coronary intervention vs thrombolysis for ST-elevation myocardial infarction. JAMA 2007 0.76
339 The international registry infrastructure for cardiovascular device evaluation and surveillance. JAMA 2013 0.76
340 Three-dimensional printing of large nasal septal perforations for optimal prosthetic closure. Am J Rhinol Allergy 2016 0.76
341 Pulmonary vein stenosis after atrial fibrillation ablation. EuroIntervention 2016 0.75
342 Myocardial revascularization by percutaneous coronary intervention: past, present, and the future. Curr Probl Cardiol 2011 0.75
343 Reply: Is CABG Superior to DES for Repeat Revascularization in Patients With Isolated Proximal LAD Disease? J Am Coll Cardiol 2015 0.75
344 Letter by Tomaselli and Holmes regarding article, "2011 ASA/ACCF/AHA/AANN/AANS/ACR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease". Circulation 2012 0.75
345 The process of bringing new drug-eluting stents to market will they see the light of day? JACC Cardiovasc Interv 2008 0.75
346 Unprotected left main percutaneous coronary intervention. Rev Cardiovasc Med 2002 0.75
347 Clinical and economic outcomes after introduction of drug-eluting stents. Am J Manag Care 2010 0.75
348 Toward modeling of radio-frequency ablation lesions for image-guided left atrial fibrillation therapy: model formulation and preliminary evaluation. Stud Health Technol Inform 2013 0.75
349 How did we get here from there? Catheter Cardiovasc Interv 2003 0.75
350 Resistance to what, does it matter? How do we study it? Eur Heart J 2008 0.75
351 Pulse transmission coefficient: a nonhyperemic index for physiologic assessment of procedural success following percutaneous coronary interventions. Catheter Cardiovasc Interv 2004 0.75
352 Next-generation drug-eluting stents: a spirited step forward or more of the same. JAMA 2008 0.75
353 Pulse transmission coefficient: a novel nonhyperemic parameter for assessing the physiological significance of coronary artery stenoses. J Am Coll Cardiol 2002 0.75
354 Predictors of failure of endovascular therapy for peripheral arterial disease. Angiology 2006 0.75
355 Bridging and spasming. Tex Heart Inst J 2012 0.75
356 Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. Am Heart J 2007 0.75
357 Do we need a better mouse trap? Eur Heart J 2010 0.75
358 Coronary artery fistula with anomalous coronary artery origin: a case report. J Am Soc Echocardiogr 2007 0.75
359 A better way to get there? Catheter Cardiovasc Interv 2007 0.75
360 Reply: Left Atrial Appendage Occlusion Devices Versus Pharmacological Agents for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol 2015 0.75
361 Guidelines, lighthouses, and a toe in the water. Circulation 2005 0.75
362 Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers. Med Devices (Auckl) 2009 0.75
363 Interventional cardiology: A new drug-eluting stent that does not live up to its promise. Nat Rev Cardiol 2009 0.75
364 Day in and day out. Catheter Cardiovasc Interv 2004 0.75
365 Interventional cardiology: Don't neglect the octogenarians--DES for everyone!? Nat Rev Cardiol 2012 0.75
366 Venn diagrams in cardiovascular disease: the Heart Team concept. Eur J Cardiothorac Surg 2013 0.75
367 Lipid-rich plaque masquerading as a coronary thrombus. Clin Med Res 2006 0.75
368 Coming close and then pulling away. Eur Heart J 2007 0.75
369 Stenting small coronary arteries: works in progress. JAMA 2004 0.75
370 A view from within. Catheter Cardiovasc Interv 2004 0.75
371 Benefit with Impella? J Am Coll Cardiol 2010 0.75
372 Outcomes of a system-wide protocol for elective and nonelective coronary angioplasty at sites without on-site surgery: the Mayo Clinic experience. Mayo Clin Proc 2009 0.75
373 A piecewise patch-to-model matching method for image-guided cardiac catheter ablation. Comput Med Imaging Graph 2011 0.75
374 Appending Limited Clinical Data to an Administrative Database for Acute Myocardial Infarction Patients: The Impact on the Assessment of Hospital Quality. Med Care 2016 0.75
375 The effect of HapMap on cardiovascular research and clinical practice. Nat Clin Pract Cardiovasc Med 2007 0.75
376 Challenges of antiplatelet therapy in patients who require anticoagulation. J Invasive Cardiol 2009 0.75
377 Patient selection for transcatheter aortic valve replacement. J Am Coll Cardiol 2013 0.75
378 The clinical development of percutaneous heart valve technology. J Thorac Cardiovasc Surg 2005 0.75
379 Angiography and interventional cardiology. J Am Coll Cardiol 2004 0.75
380 President's page: Wrinkling the soul. J Am Coll Cardiol 2011 0.75
381 Abciximab readministration. Rev Cardiovasc Med 2002 0.75
382 ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. J Am Coll Cardiol 2011 0.75
383 Elective percutaneous coronary intervention without on-site cardiac surgery: clinical and economic implications. Med Care 2006 0.75
384 President's page: clouds, science, and education. J Am Coll Cardiol 2011 0.75
385 Evidence of a topographical link between unstable carotid plaques and luminal stenosis: can we better stratify asymptomatic patients with significant plaque burden? Int J Cardiol 2011 0.75
386 Late DES thrombosis: a lot of smoke, very little fire? Catheter Cardiovasc Interv 2007 0.75
387 Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. EuroIntervention 2016 0.75
388 Academic technology transfer and radiology: a strong partnership for the future. Acad Radiol 2007 0.75
389 Cutting balloon angioplasty vs. conventional balloon angioplasty in patients receiving intracoronary brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv 2004 0.75
390 Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation: a substudy from the Synergy between Percutaneous Coronary Interventions with Taxus and Cardiac Surgery (SYNTAX) Trial. Int J Cardiol 2013 0.75
391 Feasibility and effectiveness of massage therapy for symptom relief in cardiac catheter laboratory staff: a pilot study. Complement Ther Clin Pract 2011 0.75
392 Percutaneous left atrial appendage obliteration. JACC Cardiovasc Imaging 2008 0.75
393 Simulation: present and future roles. JACC Cardiovasc Interv 2008 0.75
394 Integrated management of patients with diabetes mellitus and ischemic heart disease: PCI, CABG, and medical therapy. Curr Probl Cardiol 2005 0.75
395 Left atrial appendage occlusion for stroke prevention. Curr Probl Cardiol 2015 0.75
396 President's page: measuring and other things. J Am Coll Cardiol 2011 0.75
397 Reply: Incomplete Revascularization in PCI and CABG: When Two Plus Two Does Not Make Four. J Am Coll Cardiol 2016 0.75
398 Ethical issues in cardiovascular research involving humans. Circulation 2009 0.75
399 Venn diagrams in cardiovascular disease: the Heart Team concept. Ann Thorac Surg 2013 0.75
400 Interventional fellowship in structural and congenital heart disease for adults. Catheter Cardiovasc Interv 2010 0.75
401 The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry. JACC Cardiovasc Interv 2012 0.75
402 Residual leaks following percutaneous left atrial appendage occlusion: assessment and management implications. EuroIntervention 2017 0.75
403 ACCF and AHA Presidents' Letter on MEDCAC. J Am Coll Cardiol 2012 0.75
404 Coronary intervention in thrombus-rich lesions: beyond stents and glycoprotein IIb/IIIa inhibitors. Isr Med Assoc J 2003 0.75
405 President's page: Having light, pass it on. J Am Coll Cardiol 2007 0.75
406 Percutaneous left ventricular assist device with TandemHeart for high-risk percutaneous coronary intervention: the Mayo Clinic experience. Catheter Cardiovasc Interv 2012 0.75
407 Axillary artery conduit formation for arterial access during transapical transcatheter aortic valve replacement. J Card Surg 2014 0.75
408 Access site for cardiac catheterization. Am Heart J 2004 0.75
409 Update on dual antiplatelet therapy for percutaneous coronary intervention. Heart 2009 0.75
410 President's page: i2 Summit 2006: one-stop shopping for interventionalists. J Am Coll Cardiol 2005 0.75
411 Delayed transcatheter heart valve migration and failure. JACC Cardiovasc Imaging 2014 0.75
412 Percutaneous Transcatheter Biopsy for Intracardiac Mass Diagnosis. EuroIntervention 2017 0.75
413 Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study. EuroIntervention 2015 0.75
414 An update on transcatheter aortic valve replacement. Curr Probl Cardiol 2013 0.75
415 Simulated imaging of atherosclerotic & radiofrequency ablation lesions using phase subtraction. Conf Proc IEEE Eng Med Biol Soc 2015 0.75
416 Percutaneous left atrial appendage occlusion in 2016. EuroIntervention 2016 0.75
417 President's page: acute coronary care: the yardstick of value. J Am Coll Cardiol 2006 0.75
418 Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: an analysis of the SYNTAX study. Catheter Cardiovasc Interv 2014 0.75
419 Fast adaptation of pre-operative patient specific models to real-time intra-operative volumetric data streams. Stud Health Technol Inform 2011 0.75
420 Assessing hospital performance for acute myocardial infarction: how should emergency department transfers be attributed. Med Care 2015 0.75
421 Anticipated impact of drug-eluting stents on referral patterns for coronary artery bypass graft surgery: a population-based angiographic analysis. Mayo Clin Proc 2004 0.75
422 President's page: heroes and the shoulders of giants. J Am Coll Cardiol 2012 0.75
423 Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. Heart Surg Forum 2013 0.75
424 Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS). EuroIntervention 2011 0.75
425 Unrestricted availability of intracoronary stents is associated with decreased abrupt vascular closure rates and improved early clinical outcomes. Catheter Cardiovasc Interv 2002 0.75